hydrocotarnine has been researched along with Neoplasms in 5 studies
hydrocotarnine: RN given refers to parent cpd; structure in Merck, 9th ed, #4679
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In Japan, although oral oxycodone is widely used for cancer pain treatment, there is no injection preparation of oxycodone used as a single ingredient." | 7.78 | [Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration]. ( Akagi, T; Kudo, N; Matoba, M; Miura, K; Murakami, S; Saito, O; Sano, T; Shuto, C; Yamamoto, H; Yokote, N, 2012) |
| "Compound injections of oxycodone and hydrocotarnine are currently used as one of the treatment options for some cases with cancer pain." | 7.74 | Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2007) |
| "The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan." | 7.74 | [Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain]. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Nakamura, K; Yago, K, 2007) |
| "In Japan, although oral oxycodone is widely used for cancer pain treatment, there is no injection preparation of oxycodone used as a single ingredient." | 3.78 | [Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration]. ( Akagi, T; Kudo, N; Matoba, M; Miura, K; Murakami, S; Saito, O; Sano, T; Shuto, C; Yamamoto, H; Yokote, N, 2012) |
| "Compound injections of oxycodone and hydrocotarnine are currently used as one of the treatment options for some cases with cancer pain." | 3.74 | Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2007) |
| "The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan." | 3.74 | [Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain]. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Nakamura, K; Yago, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Sano, T | 1 |
| Akagi, T | 1 |
| Yokote, N | 1 |
| Shuto, C | 1 |
| Kudo, N | 1 |
| Miura, K | 1 |
| Murakami, S | 1 |
| Saito, O | 1 |
| Yamamoto, H | 1 |
| Matoba, M | 4 |
| Kokubun, H | 3 |
| Ouki, M | 1 |
| Kubo, H | 1 |
| Hoka, S | 3 |
| Yago, K | 3 |
| Fukawa, M | 2 |
| Yamada, Y | 1 |
| Nakamura, K | 1 |
1 review available for hydrocotarnine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
4 other studies available for hydrocotarnine and Neoplasms
| Article | Year |
|---|---|
[Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Ch | 2012 |
Determination of oxycodone and hydrocotarnine in cancer patient serum by high-performance liquid chromatography with electrochemical detection.
Topics: Analgesics, Opioid; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Neoplasms; Oxyco | 2005 |
Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Female; Humans; Infusions, Intravenous; Logistic Models; Male; Meta | 2007 |
[Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain].
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Delayed-Action Preparations; Fema | 2007 |